Third Rock Ventures has led a series A round for Abata Therapeutics, launched by the firm to commercialise research from Harvard, MIT, Johns Hopkins, NIH and UZH.

Abata Therapeutics, a US-based cell therapy developer focused on autoimmune and inflammatory diseases, has launched with $95m in series A financing led by Third Rock Ventures to advance research from multiple institutions. Gene and cell therapy developer ElevateBio, Lightspeed Venture Partners, Invus, Samsara BioCapital and the JDRF T1D Fund participated in the round, which followed…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.